Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Clinical Data
Biotech
PTC and Novartis’ Huntington's data fail to convince investors
Investors wiped almost 20% off PTC’s share price amid doubts about the path to accelerated approval of the asset.
Nick Paul Taylor
May 6, 2025 7:25am
Aldeyra posts hit, miss for dry eye drug, plans FDA filing
May 6, 2025 7:05am
Pfizer ties PD-1 drug to 32% cancer risk reduction in phase 3
Apr 28, 2025 7:25am
Bioxodes halts phase 2 stroke trial after interim review success
Apr 24, 2025 9:32am
Sanofi's oral TNF asset misses mark in phase 2 psoriasis trial
Apr 24, 2025 4:46am
Ascletis sees no benefit to high, fast oral GLP-1 dose titration
Apr 23, 2025 7:25am
